Share

August 20, 2019; 93 (8) Article

Cognitive heterogeneity in probable Alzheimer disease

Clinical and neuropathologic features

Yuqi Qiu, Diane M. Jacobs, Karen Messer, David P. Salmon, Howard H. Feldman
First published July 18, 2019, DOI: https://doi.org/10.1212/WNL.0000000000007967
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
328

Share

Article Information

vol. 93 no. 8 e778-e790
DOI: 
https://doi.org/10.1212/WNL.0000000000007967
PubMed: 
31320469
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received October 18, 2018
  • Accepted in final form March 28, 2019
  • First Published July 18, 2019.

Article Versions

Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    1. Yuqi Qiu, MS,
    2. Diane M. Jacobs, PhD,
    3. Karen Messer, PhD,
    4. David P. Salmon, PhD and
    5. Howard H. Feldman, MD, FRCP
  1. Yuqi Qiu, MS,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Diane M. Jacobs, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIA/NIH, P50 AG05131, Co-Investigator, 2016-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Karen Messer, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Tobacco Control, statistical editor, 2010 to present

    Patents:

    1. ?Phospholipid conjugates of immune response activators for treatment of cancer?- pending "Ultilization of Dimethylfumarate (DMF) for the treatment of chronic lymphocytic leukemia." - pending

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Fulcrum Therapeutics

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 2P30CA023100-28 (Lippman, Scott) 05/01/14-04/30/19 1.44 calendar mos. NIH/NCI $2,703,607 Specialized Cancer Center Support Grant Dr. Messer is the Director of the Biostatistics Shared Resource. The goals of this grant are to reduce the morbidity and mortality from cancer in San Diego County. Role: Director of the Biostatistics Shared Resource HHSN272201400051C (Carson) 09/30/14-09/29/19 0.43 calendar mos NIAID $ 1,146,909 Title: Adjuvant Discovery for Vaccines against West Nile Virus and Influenza The early stage discovery and initial characterization of novel adjuvant candidates for vaccines Role: Co-Investigator 1R01DE026644 (Gutkind) 01/01/17-12/31/21 0.6 calendar mos. NIDCR $285,092 Title: Targeting Signaling Vulnerabilities for Oral Cancer Prevention The long-term goal of our team effort is to define mechanism-based biomarkers predicting a response to metformin and suitable therapeutic options to overcome drug resistance. Ultimately, our planned studies will provide the foundation for patient selection (enrichment) for the design and implementation of future OSCC precision prevention trials. Role: Co-Investigator R01DE027325 (Varner) 09/15/17-08/31/22 0.6 Calendar mos. NIDCR $301,950 Title: Targeting the Innate Immune Response in HNSCC We propose to test the overall hypothesis that therapeutic strategies that block macrophage-mediated immune suppression will synergize with T cell targeted therapeutics to improve outcomes in HNSCC disease. Role: Co-Investigator R01CA220009 (Zanetti) 08/17/17-07/31/22 0.36 Calendar mos NCI $200,000 Title: (PQ3) Disruption of Immune Surveillance by Aneuploidy and Aberrant MHCII Expression We will test the hypothesis that high level aneuploidy and low level expression of MHC II molecules in tumors form a barrier against immune surveillance hindering immunotherapy interventions in patients. Role: Co-Investigator UL1TR001442 (Firestein) 08/13/15-03/31/20 1.8 calendar mos NCATS $5,592,000 Title: UC San Diego Clinical and Translational Research Institute The UCSD CTRI will support and transform clinical research by providing guidance and support from initial planning of research through data analysis and dissemination. The CTRI will foster development of novel technologies that facilitate clinical research and support investigators by providing the services needed to conduct clinical research and improve health. Role: Co-Investigator R01CA134633 (Ahrens) 05/10/09-05/31/22 0.9 Calendar mos NCI $358,181 Title: Clinical Translation of 19F MRI to Visualize Cancer Immunotherapeutic Cells This project aims to use a novel magnetic resonance imaging (MRI) technology to visualize the trafficking of curative tumor infiltrating lymphocytes in head and neck cancer patients. Role: Co-Investigator AC1-07764 (Jamieson) 02/01/17-01/31/20 1.2 Calendar mos CIRM $1,337,850 Title: Alpha Stem Cell Clinic for the Development of Regenerative Therapies The clinic is to provide operational support to the stem cell clinical trials while creating Accelerating and Value Add Resources to accelerate and remove bottlenecks to the conduct of the trials. Role: Co-Investigator R01AG055523 (Mobley) 05/01/18-01/31/23 0.6 calendar mos. NIA $345,048 Title: Treating with Gamma-Secretase modulators to prevent neurodegeneration in mouse models of Down Syndrome and Alzheimer disease We aim to prevent Alzheimer disease (AD) in adults with DS (trisomy 21), referred to as AD in DS (AD-DS) by enhancing processing of the amyloid precursor protein (APP) to reduce the levels of the C-terminal 99 residue fragment (C99) and Aβ42. Role: Co-Investigator R01CA050286 (Cheresh) 03/04/15-02/28/20 0.36 calendar mos NIH/NCI $300,165 CRAF-mediated Vascular Resistance to Cancer Therapies This proposal is focused on how CRAF signaling in vascular cells promotes endothelial cell survival and resistance to different forms of cellular stresses present within the tumor microenvironment. Role: Co-Investigator

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Breath of Hope Foundation Grant 2017 (Bui) 05/01/17-02/28/21 0.3 Calendar mos Moores Cancer Center Pilot Projects $50,000 Title: Engineering lung cancer cells into immune stimulatory dendritic cells In order to improve responses to anti-PD-1 in non-small cell lung cancer, we hypothesize that administration of dendritic cell (DC) vaccines would increase the proliferation of responding T-cells while also providing more precursor T- cells to respond to anti-PD-1. To generate optimal DC vaccines, we will induce lung cancer cells to transdifferentiate into DCs while also transducing the cells with stimulatory proteins such as IL-17D. Role: Co-Investigator V Foundation (Contact PI: Varner) 11/01/17-10/31/20 0.24 Calendar mos. V Foundation $200,000 Title: Novel Strategies to Break Cancer Immune Tolerance This project will develop novel therapeutic approaches for HNSCC that are based on the inherent interplay of this cancer with the tumor immune microenvironment, using agents that are already in clinical development. Role: Co-Investigator

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. David P. Salmon, PhD and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Takeda Pharmaceuticals Aptinyx, Inc.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIA P50 AG05131, Co-investigator, 2014-2019 (2) NIA U19 AG10483, Co-Investigator, 2012-2020 (3) NIH R01 DC011492, Co-Investigator, 2015-2020 (4) NIA R01 AG049810, Co-Investigator, 2015-2020 (5) NIA R01 AG054509, Co-Investigator, 2017-2021 (6) NIA R01 AG054049, Co-Investigator, 2017-2022 (7) NIA U2C AG057441, Site Principal Investigator, 2018-2021 (8) CA DHS 20124096, Co-Investigator, 2002-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Howard H. Feldman, MD, FRCP
    6. Scientific Advisory Boards:

    1. Payments for service agreements to University of British Columbia or University of California, San Diego for 1. Commercial; Genentech/Banner Health: Diagnostic Monitoring Committee 2. Commercial Eisai LTD: Data Safety Monitoring Board 3. Commercial Tau Rx: Scientific Advisory Board 4. Commercial Merck Pharmaceutical: Advisory Board 5. Commercial Axon Neurosciences: Advisory Board 6. Samus Therapeutics: Advisory Board 7. Toyama Pharmaceuticals: Advisory Board 8. Commercial Arkuda Therapeutics: Advisory Board 9. Commercial Samumed: Advisory Board 10.Commercial Genentech: Data and Safety Monitoring Board 11. Not for Profit: Tau Consortium: Scientific Advisory Board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Not for Profit: Tau Consortium Investigator Meetings (travel expenses) 2. Commercial: Medscape (lecture honorarium to UCSD) 3. Commercial: Optum (Lecture honorarium to UCSD) 4. Commercial: Axon Neurosciences (meeting travel reimbursement to UCSD) 5. Commercial: Probiodrug (meeting travel reimbursement) 4. Not for Profit: Brain Canada 2014 (travel expenses)

    Editorial Boards:

    1. Journal of Prevention of Alzheimer's Disease 2014-present (editorial board) Alzheimer's & Dementia Translational Research and Clinical Interventions 2014-present (editorial board) Dementia and Geriatric Cognitive Disorders (editorial board)

    Patents:

    1. US Serial Number PCT/2007/070008 Detecting and Treating Dementia

    Publishing Royalties:

    1. Royalties from the book Atlas of Alzheimer?s Disease (2007) Informa Health London

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Commercial Samus consulting service agreement with UCSD 2. Commercial Axon Neurosciences consulting service agreement with UCSD 3. Commercial Tau Rx Consulting service agreement with UCSD

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Non-profit Washington University grant review Non-profit Alzheimer Drug Discovery Foundation grant review

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Director of the Alzheimer Disease Cooperative Study (April 2016-present)which has undertaken clinical trials with study sponsors AC Immune (2016-2020), Toyama Pharmaceuticals (2016-2018), Probiodrug (2018), Biohaven Pharmaceuticals (2018-2021) and QR Pharma (2016-2020).NOt for profit LuMind ADCS 059 LIFE DSR (2018-2021)

    Research Support, Government Entities:

    1. 1. Canadian Institutes of Health Research CIHR # 287674 (2013-18)role co Principal Investigator, 2. CIHR Consortium for Neurodegeneration and Aging # 137794,co Principal Investigator and Member Research Executive(2014-19)Grant 3. CIHR and Weston Foundation Intranasal Oxytocin for FTD Co-Investigator (2016-2020) 5. University of California Cure AD: Salsalate in AD Co- Investigator (2016-2018) 6. National Institute on Aging P50 AG 005131 UCSD Alzheimer's Disease Research Center 7. National Institute on Aging 5RO1 AG047922 2016-2019 8. National Institute on Aging U19 AG010483 2016-2021 9. UC Cures for Alzheimer's Disease Nicotinamide in 2016- 2019 10. National Institute on Aging UF1AG032438 2016-2018 11. Brain Canada #4469 2018-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Non profit LuMind ADCS 059 LIFE DSR (2018-2021)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Family Medicine and Public Health (Y.Q., K.M.), Department of Neurosciences (D.M.J., D.P.S., H.H.F.), and Shiley-Marcos Alzheimer's Disease Research Center (D.M.J., D.P.S., H.H.F.), University of California, San Diego, La Jolla.
  1. Correspondence
    Dr. Feldman hhfeldman{at}ucsd.edu
View Full Text

Article usage

Article usage: July 2019 to April 2022

AbstractFullPdfSource
Jul 2019808032Highwire
Aug 20194713842Highwire
Sep 20192612530Highwire
Oct 20191962524Highwire
Nov 20191531217Highwire
Dec 201984514Highwire
Jan 20201491218Highwire
Feb 20201322031Highwire
Mar 2020136623Highwire
Apr 20201121127Highwire
May 202016926Highwire
Jun 20204249Highwire
Jul 20208825Highwire
Aug 20207228Highwire
Sep 20207223Highwire
Oct 20207302Highwire
Nov 20205035Highwire
Dec 20205201Highwire
Jan 20212822Highwire
Feb 20213354Highwire
Mar 20216142Highwire
Apr 20215464Highwire
May 20214400Highwire
Jun 20216322Highwire
Jul 20215811Highwire
Aug 20215544Highwire
Sep 20214913Highwire
Oct 20218825Highwire
Nov 20215351Highwire
Dec 20214400Highwire
Jan 20224000Highwire
Feb 20227632Highwire
Mar 20225210Highwire
Apr 20223401Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me